News for Healthier Living

New Therapeutic Target Expands Options for Multiple Myeloma

In a Phase I clinical trial, the investigational bispecific antibody cevostamab reduced cancer in more than 40% of patients with multiple myeloma.

July 22, 2026


July 22 2026

July 21 2026

July 20 2026

July 17 2026

July 16 2026

July 15 2026

July 14 2026

July 13 2026

July 12 2026

July 10 2026

July 9 2026

July 8 2026